157327-41-8

Usage

Uses

Used in Medicinal Chemistry:
1-Boc-3-[(Dimethylamino)methylene]-4-oxopiperidine is used as a reagent or intermediate for the development of pharmaceuticals and bioactive molecules, leveraging its unique structural features to enhance the properties of synthesized compounds.
Used in Organic Synthesis:
N-Boc-DMA-Pip is used as a building block in the synthesis of complex organic molecules, contributing to the creation of diverse chemical structures with potential applications in various fields.
Used in Asymmetric Synthesis:
1-Boc-3-[(Dimethylamino)methylene]-4-oxopiperidine is used as a chiral auxiliary in asymmetric synthesis, facilitating the production of enantiomerically pure compounds, which are crucial in pharmaceutical development and other applications where stereochemistry is important.
Used in Organic Transformations:
N-Boc-DMA-Pip is utilized as a catalyst in organic transformations, improving the efficiency and selectivity of various chemical reactions, thereby contributing to the advancement of synthetic methodologies.

InChI:InChI=1/C13H22N2O3/c1-13(2,3)18-12(17)15-7-6-11(16)10(9-15)8-14(4)5/h8H,6-7,9H2,1-5H3/b10-8-

Upstream product

• 127-19-5 N,N-dimethyl acetamide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 900156-22-1 tert-butyl 2-methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate 
• 869198-95-8 2-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylic acid tert-butyl ester 
• 1613148-19-8 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)pyridin-2-amine 
• 1454657-06-7 3-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-N-[3-(trifluoromethyl)phenyl]benzamide 
• 1454656-96-2 N-(3-isopropylphenyl)-4-methyl-3-[2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]benzamide 
• 1454656-93-9 3-[2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-N-[3-(trifluoromethyl)phenyl]benzamide 
• 1454657-51-2 methyl-4-methyl-3-[2-(methylsulfanyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-6-yl]benzoate 
• 1454656-60-0 N-(4-isopropylphenyl)-6-[2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]pyridine-2-carboxamide 
• 1454656-47-3 6-{2-amino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-6-yl}-N-[4-(isopropyl)phenyl]pyridine-2-carboxamide 
• 1454656-61-1 6-(2-methanesulfinyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-pyridine-2-carboxylic acid (4-isopropyl-phenyl)-amide 
• 1383776-02-0 tert-butyl 2-(m-tolylamino)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate 
• 1383776-12-2 N-(3-chlorophenyl)-6-(1-isopropyl-1H-tetrazol-5-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine 
• 1383776-10-0 6-(1-(tert-butyl)-1H-tetrazol-5-yl)-N-(3-chlorophenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine 

Relevant academic research and scientific papers

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold

A series of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold were identified with good cellular and human whole blood activity against IDO1. These inhibitors contain multiple chiral centers and all diastereomers were separated. The absolute stereochemistry of each isomers were not determined. Compounds 15 and 27 stood out as leads due to their good cellular as well as human whole blood IDO1 inhibition activity, low unbound clearance, and reasonable mean residence time in rat cassette PK studies.

NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula (I) wherein R1, R2 and Z are as described herein, compositions including the compounds and methods of using the compounds.

2-(2-pyridine)-6-(2-chloro-3-trifluoromethylbenzoyl)-5,7,8-trihydropyrido [4,3-d] pyrimidine and preparation method thereof

The invention discloses 2-(2-pyridine)-6-(2-chloro-3-trifluoromethylbenzoyl)-5,7,8-trihydropyrido [4,3-d] pyrimidine and a preparation method thereof. The structure of the 2-(2-pyridine)-6-(2-chloro-3-trifluoromethylbenzoyl)-5,7,8-trihydropyrido [4,3-d] pyrimidine is as shown in the formula (I), and the 2-(2-pyridine)-6-(2-chloro-3-trifluoromethylbenzoyl)-5,7,8-trihydropyrido [4,3-d] pyrimidine belongs to a novel pyridopyrimidine compound and a novel anticancer drug is provided for human beings. The research field of pyridopyrimidine compounds is widened, the reaction total yield of the compound is high, the process is simple, and the method is suitable for industrial production.

FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

Pyridopyrimidine compounds and preparation method thereof

The invention discloses pyridopyrimidine compounds and a preparation method thereof. The pyridopyrimidine compounds are 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines; and the derivatives are 2-(2-pyridyl)-6-(2,3-dichlorobenzoyl)-5,7,8-trihydrop

Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2

This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

BICYCLIC PYRAZOLE PESTICIDES

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, (1) wherein Q is (Q-1) or (Q-2); and A, R1, m, X1, X1a, X1b, X2, R2, R5, q and t are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90

Heat shock protein 90 (Hsp90) is a potential target for oncology therapeutics. Some inhibitors have shown antitumor effects in clinical trials, spurring the discovery of small molecule Hsp90 inhibitors. Here, we describe the structural optimization studies of a hit compound, tetrahydropyrido[4,3-d]pyrimidine-based Hsp90 inhibitor 15, which exhibits inhibitory activity against Hsp90. A series of analogues were synthesized, and their structure-activity and structure-property relationships were analyzed. These explorations led to the discovery of compound 73, which exhibited potent in vitro activities, good physicochemical properties, favorable ADME properties, and a potent antitumor effect in an HCT116 xenograft model. Furthermore, 73 exhibited no ocular toxicity in a rat retinal damage model, suggesting it is a relatively safe Hsp90 inhibitor. As a promising antitumor agent, 73 was progressed for further preclinical evaluation.

TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS

The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.